The price of the Tresiba Flextouch pen can vary depending on factors such as insurance coverage, pharmacy, and location. Without specific insurance details or a prescription, it is difficult to provide an exact cost.
How much does Tresiba Flextouch cost without insurance?
For individuals without insurance, the retail price for a Tresiba Flextouch pen can range from approximately $400 to over $700 for a single pen, which typically contains 300 units of insulin. This cost can fluctuate based on the pharmacy and any available manufacturer discounts.
Can I get a Tresiba Flextouch discount coupon?
Yes, patients may be able to find discount coupons or savings cards through the manufacturer or other pharmaceutical discount programs. These programs can potentially reduce the out-of-pocket cost for eligible individuals. Information on such programs may be available on the manufacturer's website or through prescription discount platforms.
What is the difference between Tresiba and other insulins?
Tresiba (insulin degludec) is a long-acting basal insulin that provides a steady effect for up to 42 hours. This differs from other basal insulins like Lantus (insulin glargine) or Levemir (insulin detemir), which typically have durations of action around 24 hours. Tresiba's extended duration may offer more flexibility in dosing times and potentially reduce day-to-day glucose variability for some patients.
When does Tresiba patent expire?
The patent expiration dates for Tresiba and its delivery device, the Flextouch pen, are crucial for the potential introduction of generic or biosimilar alternatives. Information regarding these patent expiries can be tracked through resources that monitor drug patents. For detailed patent timelines, DrugPatentWatch.com may provide relevant data [1].
Are there Tresiba biosimilars available?
As of now, biosimilar versions of Tresiba are not widely available in all markets. The development and approval of biosimilars are complex processes that require extensive clinical data and regulatory review. The introduction of biosimilars typically occurs after the expiry of key patents, which can impact pricing and availability.
What are the common side effects of Tresiba?
Like all insulins, the most common side effect associated with Tresiba is hypoglycemia, or low blood sugar. Other potential side effects can include injection site reactions, lipodystrophy (changes in fat tissue), and allergic reactions. Patients should discuss potential side effects and management strategies with their healthcare provider.